REGULAR CONTENT
Final ID
495
Type
Original Scientific Research-Oral or Pos
Authors
R Yamada1, F Alam1, S Bracewell2, S Volin3, L Dufour4, J Camacho5, M Guimaraes1, S Bracewell2
Institutions
1Medical University of South Carolina, Charleston, SC, 2MUSC Department of Radiology, Charleston, SC, 3N/A, Falmouth, ME, 4N/A, Charleston, SC, 5N/A, Atlanta, GA
Purpose
To determine safety and efficacy of combined cTACE and PTA for unresectable HCC.
Materials & Methods
IRB approval was granted and retrospective analysis was conducted in our database to identify patients with unresectable HCC who underwent cTACE followed by PTA from 2007-2016. cTACE was performed with a mixture of Lipiodol® (Guerbet, Villepinte, Fr), Mitomycin and Polyvinyl Alcohol particles (300-500um). PTA was performed with radiofrequency or microwave energy with Cool Tip® probes or Evident® antennas (Covidien, Dublin, Ireland). Efficacy was assessed by overall survival (OS), time to progression (TTP) and treatment response via mRECIST criteria.Safety was assessed according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Results
Sixty nine (n=69) patients were identified (15 females; 54 males) with unresectable HCC who underwent cTACE followed by PTA from 2007-2016. Mean age was 63 years (84 - 44). Average MELD score was 9.5. Child-Pugh A, B and C patients were 53 (76%), 15(21%) and 1(3%), respectively. Mean lesion size was 4.4 cm (16.2 – 1.3 cm). The overall survival was 31.9 months with time to progression of 13.2 months. On one- month follow-up imaging 41 (59.4%) patients had complete response, 21 (30.4%) patients had partial response, and 6 (8.6%) patients had disease progression. Objective response was achieved in 62 patients (89.9%). Images were not available in one patient. 6 complications were reported, three grade 1 (bradycardia), two grade 2 (seizure; pneumothorax) and one grade 4 (acute bleeding).
Conclusions
cTACE followed by PTA is an effective and safe treatment approach to unresectable HCC.
Final ID
495
Type
Original Scientific Research-Oral or Pos
Authors
R Yamada1, F Alam1, S Bracewell2, S Volin3, L Dufour4, J Camacho5, M Guimaraes1, S Bracewell2
Institutions
1Medical University of South Carolina, Charleston, SC, 2MUSC Department of Radiology, Charleston, SC, 3N/A, Falmouth, ME, 4N/A, Charleston, SC, 5N/A, Atlanta, GA
Purpose
To determine safety and efficacy of combined cTACE and PTA for unresectable HCC.
Materials & Methods
IRB approval was granted and retrospective analysis was conducted in our database to identify patients with unresectable HCC who underwent cTACE followed by PTA from 2007-2016. cTACE was performed with a mixture of Lipiodol® (Guerbet, Villepinte, Fr), Mitomycin and Polyvinyl Alcohol particles (300-500um). PTA was performed with radiofrequency or microwave energy with Cool Tip® probes or Evident® antennas (Covidien, Dublin, Ireland). Efficacy was assessed by overall survival (OS), time to progression (TTP) and treatment response via mRECIST criteria.Safety was assessed according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Results
Sixty nine (n=69) patients were identified (15 females; 54 males) with unresectable HCC who underwent cTACE followed by PTA from 2007-2016. Mean age was 63 years (84 - 44). Average MELD score was 9.5. Child-Pugh A, B and C patients were 53 (76%), 15(21%) and 1(3%), respectively. Mean lesion size was 4.4 cm (16.2 – 1.3 cm). The overall survival was 31.9 months with time to progression of 13.2 months. On one- month follow-up imaging 41 (59.4%) patients had complete response, 21 (30.4%) patients had partial response, and 6 (8.6%) patients had disease progression. Objective response was achieved in 62 patients (89.9%). Images were not available in one patient. 6 complications were reported, three grade 1 (bradycardia), two grade 2 (seizure; pneumothorax) and one grade 4 (acute bleeding).
Conclusions
cTACE followed by PTA is an effective and safe treatment approach to unresectable HCC.